0-25-09 Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ion Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** 10/091,759 TRANSMITTAL Filing Date March 5, 2002 **FORM** First Named Inventor Adnan M. M. Mjalli Art Unit 1621 **Examiner Name** Peter G. O'Sullivan (to be used for all correspondence after initial filing) Attorney Docket Number TTP 2001-21 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC ✓ Petition Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a After Final Proprietary Information Provisional Application Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Identify Terminal Disclaimer Extension of Time Request below): Express Mail Certificate; Return Postcard Request for Refund Express Abandonment Request CD, Number of CD(s) Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Signature Printed name Samuel B. Rollins Date Reg. No. October 22, 2004 52.180

## CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature Date

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



## **EXPRESS MAIL CERTIFICATE**

"Express Mail" Label No.

US 507590040 US

Serial No.

10/091,759

Applicant(s)

Adnan M.M. Mjalli et al.

Filing Date

March 5, 2002

Title:

CARBOXAMIDE DERIVATIVES AS THERAPEUTIC

**AGENTS** 

Examiner

Peter G. O'Sullivan

Group Art Unit

1621

Type of Document(s)

Express Mail Certificate; Transmittal Form; Response to

Office Action; and Return Postcard

I hereby certify that the documents identified above are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below and are addressed to Mail Stop Amendment, Commissioner for Patents, P O Box 1450, Alexandria, VA 22313-1450.

(signature)

Christine Heerschap

Date Mailed: October 22, 2004



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

Adnan M.M. Mjalli et al.

Ser. No.

10/091,759

Filing Date

March 5, 2002

For

CARBOXAMIDE DERIVATIVES AS THERAPEUTIC AGENTS

Examiner

Peter G. O'Sullivan

Art Unit

1621

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## Response

Sir:

This Response is being submitted in response to the Office Action mailed September 24, 2004.

The Current Status of the Claims is reflected in the listing of the claims which begins on page 2 of this paper.

Remarks begin on page 42 of this paper.